Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity.

By H. Maeda. Advanced Drug Delivery Reviews, 2015

1,059 citations recorded by the source corpus.

Subfields: Biomaterials, Biophysics, Materials Chemistry

View Paper: https://www.semanticscholar.org/paper/64391d3f6ce81bf240e1cac957861d29d45c3247

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

1. S. Hua
2. G. Storm

In Biophysics

1. G. Storm

In Materials Chemistry

1. G. Storm

Citations in the corpus

• Nanomedicine in cancer therapy (2023, background): “23,48 61 – 64 In addition, tumor vasculature occlusion or embolization, which was triggered by bleeding or activated fi brinolysis, can damage the EPR effect by impairing blood fl ow.”
• Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization (2018, background): “Cancer targeting of NNMs has generally been universally based on the EPR effect, despite the fact that EPR-mediated accumulation has only been reported for some tumor types (Maeda, 2015).”
• Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems (2018, background): “This phenomena is known as the enhanced permeability and retention (EPR) effect, which eventually enables the circulating nanocarriers smaller than around 150 nm to extravasate from circulation through the tumour vasculature and increase the concentration of the chemotherapeutic agents within the tu”